Optimization of current and future therapy for autoimmune diseases.
about
The expanding role of immunopharmacology: IUPHAR Review 16From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokinesMechanisms of Autoantibody-Induced Pathology.Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A.Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.Hydrogels and scaffolds for immunomodulationAntigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravisCritical role for prokineticin 2 in CNS autoimmunity.Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization.Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis InitiativeCan we vaccinate against Type 1 diabetes?Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model.Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trialControl of dichotomic innate and adaptive immune responses by artery tertiary lymphoid organs in atherosclerosis.Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Nanomaterials, Autophagy, and Lupus Disease.Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases.Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Regulatory T cell-based therapies for autoimmunity.RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis.Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen SpecificA Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.Lessons learned at the intersection of immunology and neuroscienceEffects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells.Inflammatory cytokines at the summits of pathological signal cascades in brain diseases.A Tip leads cytotoxic T cells to the crime scene in neuroinflammation.A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells.Improving animal models for nervous system disorders.Pathogenic T helper 1 cells reach the brain before T helper 17 cells, and T regulatory cells suppress them albeit incompletely.Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma.AIPpred: Sequence-Based Prediction of Anti-inflammatory Peptides Using Random Forest.Tweaking the B lymphocyte compartment in autoimmune diseases
P2860
Q26801862-35C1F750-0A67-48E8-94FF-F41B07B008C9Q27008912-695788EC-D021-4D97-B8FE-BE3CEF6033AAQ33740580-13B099F1-65B9-4F53-8A38-AF42AC5D9A7DQ34577521-A9530C71-12A6-4558-97AD-6170F951CF09Q34601386-1C10AF74-B1AB-4F22-9A52-3B3D6A03E3E8Q34725541-CF6CDAC0-C190-46D9-BE5B-87EA63BB30CCQ34755933-A3F8EE37-649E-48CB-86AA-7BC94B5DC1C1Q35409577-56BC2741-7187-4E10-B423-DF6323AC59B9Q36006004-4B1005F4-2A4F-4DEE-B5CC-20BC3E5BE075Q36154537-CFA96C9F-F284-45DF-952E-79D2D806C4A0Q36296386-E7B82516-D641-41BD-A7FA-F3BA6187DF16Q36637650-C5EDB4A2-D72C-48AE-A4BC-A747F49987A6Q36666787-57ACD363-BD32-4F98-A6A5-77CA8BCD382AQ36741859-7CFD2A34-9522-439F-975A-47CFD4F3A02DQ37267547-CBB2F1EF-D28E-4306-B202-A4E7F217F166Q38025388-B6B63BD7-8BA4-49EF-8D1B-607C994DAA2AQ38169198-2A78FDB4-AAE9-40D3-A959-B413DEBFBCFFQ38551098-B8E898BF-625F-4ED9-975C-A91D57ECD93EQ38744509-84A1C376-E855-4848-A42A-7FE80CFE72A9Q38869471-7863D489-F2FA-418D-AB9C-8289E04B90E7Q38943933-FC107DE9-4C7E-4E1B-BB18-7B4B3C21ED4DQ40035796-1A340765-35D3-408B-8496-92BDF4B59DA2Q41101351-25C2835C-9B2B-4C13-BF55-22BC335722D7Q41673068-63A1C6BA-5906-42D6-80BA-5F63F744563BQ42563457-E3345CD8-2CFE-4AC8-80DB-E9040C662625Q42936105-A331B048-3263-40D9-A00B-77C5E2B09D3EQ44433702-ECCE5B8E-14E8-491B-820A-EA5009B5A778Q45046112-38874FFB-C833-40DE-80AC-FF9FA1119C52Q46055629-80CA47B5-29D7-4190-920F-9BF41C45BBDFQ46640400-E53979E5-9953-41D5-A52F-0481293F2DA1Q48115866-71471593-484E-4B88-9194-7623D90CA6CEQ48518619-938F126B-4827-4ACF-8E6A-EFC6A53F1ABDQ49019755-7D45ACAD-9195-4C3C-B147-B2D78CFAEDF5Q50903796-DA6EFD90-9633-465E-BB30-7D1BCB4660C3Q52595216-B8F43738-C43E-466D-8452-67E4205B1CE1Q58003021-AD4A9300-987E-43B1-84D8-88E1E78A53A0
P2860
Optimization of current and future therapy for autoimmune diseases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Optimization of current and future therapy for autoimmune diseases.
@en
Optimization of current and future therapy for autoimmune diseases.
@nl
type
label
Optimization of current and future therapy for autoimmune diseases.
@en
Optimization of current and future therapy for autoimmune diseases.
@nl
prefLabel
Optimization of current and future therapy for autoimmune diseases.
@en
Optimization of current and future therapy for autoimmune diseases.
@nl
P2860
P356
P1433
P1476
Optimization of current and future therapy for autoimmune diseases.
@en
P2093
Joan T Merrill
Lawrence Steinman
P2860
P2888
P356
10.1038/NM.2625
P407
P577
2012-01-06T00:00:00Z